PressJune 3, 2022 MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development
PressJune 3, 2022 SciSparc and Clearmind Collaboration Yields Another Patent Application for Proprietary Psychedelic Combination
PressJune 2, 2022 Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
PressJune 1, 2022 Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
BlogJune 1, 2022 Hadas Alterman & Adriana Kertzer are Humanizing the Legal Process for Psychedelics – Podcast Episode #6
BlogMay 30, 2022 Anthony Tennyson, CEO of Awakn Life Sciences Sits in the Investor Hotseat: Stream #1
PressMay 26, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
PressMay 25, 2022 PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
PressMay 24, 2022 Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
PressMay 23, 2022 Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
PressMay 20, 2022 Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction
PressMay 17, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
